|
1
|
Stålberg K, Kjølhede P, Bjurberg M,
Borgfeldt C, Dahm-Kähler P, Falconer H, Holmberg E, Staf C,
Tholander B, Åvall-Lundqvist E, et al: Risk factors for lymph node
metastases in women with endometrial cancer: A population-based,
nation-wide register study-On behalf of the Swedish Gynecological
Cancer Group. Int J Cancer. 140:2693–2700. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hwang JY, Kim DH, Bae HS, Kim ML, Jung YW,
Yun BS, Seong SJ, Shin E and Kim MK: Combined oral
medroxyprogesterone/levonorgestrel-intrauterine system treatment
for women with grade 2 stage IA endometrial cancer. Int J Gynecol
Cancer. 27:738–742. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu J, Tang Q, Yang L, Chen Y, Zheng F and
Hann SS: Interplay of DNA methyltransferase 1 and EZH2 through
inactivation of Stat3 contributes to β-elemene-inhibited growth of
nasopharyngeal carcinoma cells. Sci Rep. 7:5092017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang M, Hou J, Wang Y, Xie M, Wei C, Nie
F, Wang Z and Sun M: Long noncoding RNA LINC00673 is activated by
SP1 and exerts oncogenic properties by interacting with LSD1 and
EZH2 in gastric cancer. Mol Ther. 25:1014–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu F, Gu L, Cao Y, Fan X, Zhang F and
Sang M: Aberrant overexpression of EZH2 and H3K27me3 serves as poor
prognostic biomarker for esophageal squamous cell carcinoma
patients. Biomarkers. 21:80–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhai R, Tang F, Gong J, Zhang J, Lei B, Li
B, Wei Y, Liang X, Tang B and He S: The relationship between the
expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and
their impacts on prognosis. Onco Targets Ther. 9:6987–6998. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang H, Yu C, Chen M, Li Z, Tian S, Jiang
J and Sun C: miR-522 contributes to cell proliferation of
hepatocellular carcinoma by targeting DKK1 and SFRP2. Tumour Biol.
37:11321–11329. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang X, Cao W, Zhang J, Yan M, Xu Q, Wu X,
Wan L, Zhang Z, Zhang C, Qin X, et al: A covalently bound inhibitor
triggers EZH2 degradation through CHIP-mediated ubiquitination.
EMBO J. 36:1243–1260. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jin X, Yang C, Fan P, Xiao J, Zhang W,
Zhan S, Liu T, Wang D and Wu H: CDK5/FBW7-dependent ubiquitination
and degradation of EZH2 inhibits pancreatic cancer cell migration
and invasion. J Biol Chem. 292:6269–6280. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abdelrahman AE, Arafa SA and Ahmed RA:
Prognostic value of Twist-1, E-cadherin and EZH2 in prostate
cancer: An immunohistochemical study. Turk Patoloji Derg. Feb
4–2017.(Epub ahead of print). https://doi.org/10.5146/tjpath.2016.01392
|
|
11
|
Gardner EE, Lok BH, Schneeberger VE,
Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E,
Nguyen T, et al: Chemosensitive relapse in small cell lung cancer
proceeds through an EZH2-SLFN11 axis. Cancer Cell. 31:286–299.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gong C, Yao S, Gomes AR, Man EP, Lee HJ,
Gong G, Chang S, Kim SB, Fujino K, Kim SW, et al: KOHBRA study
group: BRCA1 positively regulates FOXO3 expression by restricting
FOXO3 gene methylation and epigenetic silencing through targeting
EZH2 in breast cancer. Oncogenesis. 5:e2142016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gharpure KM, Chu KS, Bowerman CJ, Miyake
T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN,
Rahhal TB, et al: Metronomic docetaxel in PRINT nanoparticles and
EZH2 silencing have synergistic antitumor effect in ovarian cancer.
Mol Cancer Ther. 13:1750–1757. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toyokawa G, Takada K, Okamoto T, Kozuma Y,
Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F,
et al: Elevated metabolic activity on 18F-FDG PET/CT is
associated with the expression of EZH2 in non-small cell lung
cancer. Anticancer Res. 37:1393–1401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamamoto I, Nosho K, Kanno S, Igarashi H,
Kurihara H, Ishigami K, Ishiguro K, Mitsuhashi K, Maruyama R, Koide
H, et al: EZH2 expression is a prognostic biomarker in patients
with colorectal cancer treated with anti-EGFR therapeutics.
Oncotarget. 8:17810–17818. 2017.PubMed/NCBI
|
|
16
|
Chang CJ, Yang JY, Xia W, Chen CT, Xie X,
Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC: EZH2
promotes expansion of breast tumor initiating cells through
activation of RAF1-β-catenin signaling. Cancer Cell. 19:86–100.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y,
Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, et al: EZH2 protein: A
promising immunomarker for the detection of hepatocellular
carcinomas in liver needle biopsies. Gut. 60:967–976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rao ZY, Cai MY, Yang GF, He LR, Mai SJ,
Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, et al: EZH2 supports
ovarian carcinoma cell invasion and/or metastasis via regulation of
TGF-beta1 and is a predictor of outcome in ovarian carcinoma
patients. Carcinogenesis. 31:1576–1583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Neusquen LP, Filassi JR, Fristachi CE,
Carvalho KC, Dória MT, Soares Júnior JM and Piato JR: EZH2 protein
expression and tumor response to neoadjuvant chemotherapy in
locally advanced breast cancer. Rev Bras Ginecol Obstet.
38:280–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oki S, Sone K, Oda K, Hamamoto R, Ikemura
M, Maeda D, Takeuchi M, Tanikawa M, Mori-Uchino M, Nagasaka K, et
al: Oncogenic histone methyltransferase EZH2: A novel prognostic
marker with therapeutic potential in endometrial cancer.
Oncotarget. 8:40402–40411. 2017.PubMed/NCBI
|
|
21
|
Guo ZL, Chen K, Wang XQ and Hu W:
Expression and relationship of Ezh2, Runx3 and caspase-3 in
endometrial adenocarcinoma. Zhonghua Bing Li Xue Za Zhi.
40:387–391. 2011.(In Chinese). PubMed/NCBI
|
|
22
|
Bachmann IM, Halvorsen OJ, Collett K,
Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and
Akslen LA: EZH2 expression is associated with high proliferation
rate and aggressive tumor subgroups in cutaneous melanoma and
cancers of the endometrium, prostate, and breast. J Clin Oncol.
24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ihira K, Dong P, Xiong Y, Watari H, Konno
Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, et al: EZH2
inhibition suppresses endometrial cancer progression via
miR-361/Twist axis. Oncotarget. 8:13509–13520. 2017.PubMed/NCBI
|
|
24
|
Eskander RN, Ji T, Huynh B, Wardeh R,
Randall LM and Hoang B: Inhibition of enhancer of zeste homolog 2
(EZH2) expression is associated with decreased tumor cell
proliferation, migration, and invasion in endometrial cancer cell
lines. Int J Gynecol Cancer. 23:997–1005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou J, Roh JW, Bandyopadhyay S, Chen Z,
Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, et
al: Overexpression of enhancer of zeste homolog 2 (EZH2) and focal
adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol
Oncol. 128:344–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liotta LA: Adhere, degrade, and move: The
three-step model of invasion. Cancer Res. 76:3115–3117. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liotta LA and Clair T: Cancer. Checkpoint
for invasion. Nature. 405:287–288. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liotta LA and Kohn E: Cancer invasion and
metastases. JAMA. 263:1123–1126. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang HF, Yang H, Hu LB, Lei YH, Qin Y, Li
J, Bi CW, Wang JS and Huo Q: Effect of siRNA targeting EZH2 on cell
viability and apoptosis of bladder cancer T24 cells. Genet Mol Res.
13:9939–9950. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gonzalez ME, DuPrie ML, Krueger H,
Merajver SD, Ventura AC, Toy KA and Kleer CG: Histone
methyltransferase EZH2 induces Akt-dependent genomic instability
and BRCA1 inhibition in breast cancer. Cancer Res. 71:2360–2370.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moore HM, Gonzalez ME, Toy KA,
Cimino-Mathews A, Argani P and Kleer CG: EZH2 inhibition decreases
p38 signaling and suppresses breast cancer motility and metastasis.
Breast Cancer Res Treat. 138:741–752. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gonzalez ME, Li X, Toy K, DuPrie M,
Ventura AC, Banerjee M, Ljungman M, Merajver SD and Kleer CG:
Downregulation of EZH2 decreases growth of estrogen
receptor-negative invasive breast carcinoma and requires BRCA1.
Oncogene. 28:843–853. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xia H, Yu CH, Zhang Y, Yu J, Li J, Zhang
W, Zhang B, Li Y and Guo N: EZH2 silencing with RNAi enhances
irradiation-induced inhibition of human lung cancer growth in
vitro and in vivo. Oncol Lett. 4:135–140.
2012.PubMed/NCBI
|
|
34
|
Liu Y, Liu T, Bao X, He M, Li L and Yang
X: Increased EZH2 expression is associated with proliferation and
progression of cervical cancer and indicates a poor prognosis. Int
J Gynecol Pathol. 33:218–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mattioli E, Vogiatzi P, Sun A, Abbadessa
G, Angeloni G, DUgo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G,
et al: Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53,
p16INK4A, p27KIP1, p21WAF1, Ki-67
expression patterns in gastric cancer. J Cell Physiol. 210:183–191.
2007. View Article : Google Scholar : PubMed/NCBI
|
